Cabazitaxel side effects: Prevention and management

British Journal of Medical and Surgical Urology

Volumn 4, Issue SUPPL. 1, 2011, Pages

  Lydon, Anna ^a  

^a TORBAY AND SOUTH DEVON NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIEMETIC AGENT; BICALUTAMIDE; CABAZITAXEL; CODEINE PHOSPHATE; DEXAMETHASONE; DOCETAXEL; GENTAMICIN; GONADORELIN AGONIST; GRANULOCYTE COLONY STIMULATING FACTOR; LOPERAMIDE; OCTREOTIDE; PIPERACILLIN; PROSTATE SPECIFIC ANTIGEN;

ABDOMINAL PAIN; ADJUVANT THERAPY; AGED; ALOPECIA; ANEMIA; ARTICLE; ASTHENIA; BACKACHE; BLOOD CELL COUNT; BODY TEMPERATURE MONITORING; BONE MARROW SUPPRESSION; BONE METASTASIS; CANCER PATIENT; CASE REPORT; CASTRATION RESISTANT PROSTATE CANCER; CLINICAL PRACTICE; DIARRHEA; DISEASE COURSE; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; FATIGUE; FEBRILE NEUTROPENIA; HEMATURIA; HORMONAL THERAPY; HOSPITAL ADMISSION; HUMAN; LEUKOPENIA; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; NEUTROPHIL COUNT; ONYCHOLYSIS; PATIENT SELECTION; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROSTATE CANCER; STOMATITIS; THROMBOCYTOPENIA; VOMITING;

EID: 80051690813     PISSN: 18759742     EISSN: 18759750     Source Type: Journal    
DOI: 10.1016/j.bjmsu.2011.05.005     Document Type: Article

References (20)

1. Tannock I.F., de Wit R., Berry W.R., Horti J., Pluzanska A., Chi K.N., et al. Docetaxel plus prednisolone or mitoxantrone plus prednisolone for advanced prostate cancer. N Engl J Med 2004, 351:1502-1512.
2. Petrylak D.P., Tangen C.M., Hussain M.H.A., Lara P.N., Jones J.A., Taplin M.E., et al. Docetaxel and estramustine compared with mitoxantrone and prednisolone for advanced refractory prostate cancer. N Engl J Med 2004, 351:1513-1520.
3. National Institute for Health and Clinical Excellence. Docetaxel for the treatment of hormone-refractory metastatic prostate cancer. [Technology Appraisal 101). accessed April 2011]. http://www.nice.org.uk/nicemedia/pdf/TA101guidance.pdf.
4. Fojo A.T., Menefee M. Microtubule targeting agents: basic mechanisms of multidrug resistance (MDR). Semin Oncol 2005, 32:S3-8.
5. de Bono J.S., Oudard S., Ozguroglu M., Hansen S., Machiels J.-P., Kocak I., et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 2010, 376:1147-1154.
6. Mita A.C., Denis L.J., Rowinsky E.K., de Bono J.S., Goetz A.D., Ochoa L., et al. Phase I and pharmacokinetic study of XRP6258 (RPR 116258A), a novel taxane, administered as a 1-h infusion every 3 weeks in patients with advanced solid tumors. Clin Cancer Res 2009, 15:723-730.
7. Sanofi-aventis. Press release: JEVTANA® (cabazitaxel) for prostate cancer recommended for approval in the European Union [; accessed April 2011]. http://en.sanofi-aventis.com/binaries/20110121_JEVTANA_en_tcm28-30090.pdf.
8. US Food and Drug Administration. Cabazitaxel. [; accessed April 2011]. http://www.fda.gov/AboutFDA/CentersOffices/CDER/ucm216214.htm.
9. Sartor AO, Oudard S, Ozguroglu M, Hansen S, Machiels JH, Shen L, et al. Cabazitaxel or mitoxantrone with prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel: final results of a multinational phase III trial (TROPIC). Presented at ASCO GU, San Francisco, March 2010; Abstract 9 (presentation).
10. Cancer Research UK. Performance status [; accessed April 2011]. http://www.cancerhelp.org.uk/about%20cancer/cancer-questions/performance-status%3Fvie.
11. Roach M., Hanks G., Thames H., Schellhammer P., Shipley W.U., Sokol G.H., et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOGASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys 2006, 65:965-974.
12. Beuzeboc P. Re: Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Eur Urol 2011, 59:658.
13. Aapro M.S., Cameron D.A., Pettengell R., Bohlius J., Crawford J., Ellis M., et al. EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours. Eur J Cancer 2006, 42:2433-2453.
14. Smith T.J., Khatcheressian J., Lyman G.H., Ozer H., Armitage J.O., Balducci L., et al. 2006 Update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol 2006, 24:3187-3205.
15. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology. Myeloid growth factors. Version 1.2011. National Comprehensive Cancer Network; 2011 [; accessed April 2011]. http://www.nccn.org/professionals/physician_gls/pdf/myeloid_growth.pdf.
16. South Devon Healthcare, NHS Foundation Trust. Torbay Hospital's Cancer Services team receives national recognition for life saving campaign [; accessed April 2011]. http://www.sdhct.nhs.uk/aboutus/newsandpublications/pressreleases/2011/110209_cancerteamrecievesnationalrecognition.php.
17. National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE). (Version 4.0) [; accessed April 2011]. http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf.
18. Aksoy D.Y., Tanriover M.D., Uzun O., Zarakolu P., Ercis S., Erguven S., et al. Diarrhea in neutropenic patients: a prospective cohort study with emphasis on neutropenic enterocolitis. Ann Oncol 2007, 18:183-189.
19. Minisini A.M., Tosti A., Sobrero A.F., Mansutti M., Piraccini B.M., Sacco C., et al. Taxane-induced nail changes: incidence, clinical presentation and outcome. Ann Oncol 2003, 14:333-337.
20. Scotte F., Tourani J.M., Banu E., Peyromaure M., Levy E., Marsan S., et al. Multi-centre study of a frozen glove to prevent docetaxel-induced onycholysis and cutaneous toxicity of the hand. J Clin Oncol 2005, 23:4424-4429.